Range Cancer Therapeutics Index ETFNASDAQ:CNCR
- LAST PRICE13.39
- TODAY'S CHANGE (%)-0.86 (-6.05%)
- Bid / Lots10.07/ 2
- Ask / Lots16.77/ 2
- Open / Previous Close14.25 / 14.25
- Day Range
- 52 Week Range
- Volume5,618
- Overall Morningstar Rating1 out of 5 Starsout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNCR |
|---|---|---|
| 09:32 ET | 221 | 14.25 |
| 10:09 ET | 819 | 13.64 |
| 10:33 ET | 200 | 13.5695 |
| 11:03 ET | 760 | 13.4511 |
| 11:23 ET | 100 | 13.53 |
| 12:03 ET | 731 | 13.51 |
| 12:19 ET | 100 | 13.55 |
| 12:50 ET | 381 | 13.63 |
| 01:00 ET | 150 | 13.629 |
| 01:11 ET | 500 | 13.511 |
| 01:27 ET | 100 | 13.45 |
| 04:00 ET | 100 | 13.39 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 08/20/2024 | 0.20% |
| 08/21/2024 | 0.34% |
| 08/22/2024 | 0.37% |
| 08/23/2024 | -0.47% |
| 08/26/2024 | 0.48% |
| 08/27/2024 | -0.24% |
| 08/28/2024 | -0.09% |
| 08/29/2024 | 0.18% |
| 08/30/2024 | 0.19% |
| 09/03/2024 | 0.28% |
| 09/04/2024 | 0.12% |
| 09/05/2024 | -0.15% |
| 09/09/2024 | 0.25% |
| 09/10/2024 | -0.43% |
| 09/11/2024 | -0.45% |
| 09/12/2024 | -0.27% |
| 09/13/2024 | 0.27% |
| 09/16/2024 | 0.45% |
| 09/17/2024 | -0.03% |
| 09/18/2024 | -0.18% |
| 09/19/2024 | 0.30% |
| 09/20/2024 | -0.05% |
| 09/23/2024 | 0.63% |
| 09/24/2024 | -0.22% |
| 09/25/2024 | 0.33% |
| 09/26/2024 | -0.29% |
| 09/27/2024 | 0.51% |
| 09/30/2024 | -0.32% |
| 10/01/2024 Largest Premium | 0.96% |
| 10/02/2024 | -0.41% |
| 10/03/2024 | -0.17% |
| 10/04/2024 | 0.52% |
| 10/07/2024 | -0.38% |
| 10/08/2024 | 0.28% |
| 10/09/2024 | 0.12% |
| 10/10/2024 | -0.17% |
| 10/11/2024 | 0.23% |
| 10/14/2024 | -0.26% |
| 10/15/2024 | 0.23% |
| 10/16/2024 | -0.31% |
| 10/17/2024 | 0.36% |
| 10/18/2024 | -0.19% |
| 10/21/2024 | 0.10% |
| 10/22/2024 | 0.20% |
| 10/23/2024 | -0.31% |
| 10/24/2024 | 0.30% |
| 10/25/2024 | -0.12% |
| 10/28/2024 | 0.41% |
| 10/29/2024 | -0.35% |
| 10/30/2024 | 0.02% |
| 10/31/2024 | 0.13% |
| 11/01/2024 | -0.36% |
| 11/04/2024 | -0.03% |
| 11/05/2024 | -0.51% |
| 11/06/2024 Largest Discount | -0.81% |
| 11/08/2024 | -0.39% |
| 11/11/2024 | -0.41% |
| 11/12/2024 | -0.34% |
| 11/13/2024 | 0.23% |
| 11/14/2024 | -0.28% |
| 11/15/2024 | 0.12% |
| US Stock | 86.6% |
|---|---|
| Non-US Stock | 12.7% |
| Cash | 0.8% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 99.3% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 87.3% |
|---|---|
| Europe | 4.9% |
| Asia/Oceania | 1.5% |
| Canada | 1.4% |
| Africa | 0 |
| Latin America | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Monte Rosa Therapeutics Inc | Long | 2.1% | 0.00% | $253.3K |
ImmunityBio Inc Ordinary Shares | Long | 2.1% | 0.00% | $250.0K |
Karyopharm Therapeutics Inc | Long | 1.8% | 0.00% | $216.6K |
Genelux Corp | Long | 1.8% | 0.00% | $212.3K |
Enliven Therapeutics Inc | Long | 1.7% | 0.00% | $208.4K |
Ginkgo Bioworks Holdings Inc | Long | 1.7% | 0.00% | $204.8K |
Exelixis Inc | Long | 1.7% | 0.00% | $202.4K |
Revolution Medicines Inc Ordinary Shares | Long | 1.7% | 0.00% | $201.2K |
Biomea Fusion Inc | Long | 1.6% | 0.00% | $196.6K |
RAPT Therapeutics Inc Ordinary Shares | Long | 1.6% | 0.00% | $188.8K |
Reports
- ManagedInvestmentETF11/10/24
Morningstar ETF Report
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | 1 out of 5 Stars |
| 3 Year Rating | 1 out of 5 Stars |
| 5 Year Rating | 1 out of 5 Stars |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | Range Oncology Therapeutics TR USD |
|---|---|
Category | |
Sponsor | Exchange Traded Concepts, LLC |
Inception | October 13, 2015 |
The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index. The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRsâ€) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
| Total Net Assets | $12.1M |
|---|---|
| Shares Out. | 831.0K |
| Net Asset Value (NAV) | $13.37 |
| Prem/Discount to NAV | 0.12% |
| P/E Ratio | --- |
| Dividend Yield | 0.00% |
| Dividend per Share | --- |
| Ex-Dividend Date | --- |
| Dividend Payment Date | --- |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Small Cap Value |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.79% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.79% |